Welcome to our dedicated page for E Therapeutics news (Ticker: ETXPF), a resource for investors and traders seeking the latest updates and insights on E Therapeutics stock.
E Therapeutics (ETXPF) is a clinical-stage biotechnology company pioneering RNA interference therapies through integrated AI platforms and advanced research models. This page serves as the definitive source for official updates about the company's therapeutic developments, strategic initiatives, and operational milestones.
Investors and industry observers will find timely press releases covering clinical trial progress, research collaborations, and regulatory updates. The curated collection includes financial disclosures, technology platform enhancements like the HepNet system, and leadership announcements that impact the company's trajectory in RNAi therapeutics.
All content undergoes strict verification to ensure accuracy and relevance. Users can expect updates spanning GalOmic pipeline developments, AI-driven research methodologies, and partnerships advancing novel treatment approaches. Bookmark this page for streamlined access to E Therapeutics' latest verified developments in one centralized location.
e-therapeutics announced new preclinical results for ETX-312, their GalOmic siRNA candidate for treating metabolic dysfunction-associated steatohepatitis (MASH), to be presented at EASL Congress 2025. The study using the Gubra-Amylin NASH diet-induced obese mouse model showed that ETX-312 achieved:
- Significant improvements in NAFLD Activity Score (NAS), both as monotherapy and in combination therapy - All mice on combination therapy achieved ≥2-point NAS reductions, with up to 5-point improvements - Comparable fibrosis progression slowdown to GLP-1/GIP receptor agonist or FGF-21 analogue controls - Statistically significant reductions in hepatic collagen staining and biomarkers TIMP-1 and PIIINP
The company remains on track for regulatory submission by end of 2025, with ETX-312 currently in IND-enabling studies.
e-therapeutics has announced plans to present new preclinical data for ETX-148 at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in February 2025. The presentation will showcase the efficacy and safety results of ETX-148 in murine models of haemophilia A and B. ETX-148, which is being developed for treating bleeding disorders, is currently in IND-enabling studies, with an IND submission planned for 2026.
The oral presentation, numbered OR10, will take place during the SLAM session on February 7th, 2025, at EAHAD 2025, which runs from February 4th to 7th.
e-therapeutics reported interim results and business updates for H1 2024. The company continues advancing its GalOmic pipeline, with ETX-312 progressing through IND-enabling studies for MASH treatment, targeting submission in 2025. The company strengthened its leadership team and infrastructure, partnering with AWS to enhance AI capabilities. Financial highlights include a cash position of £41.0 million as of July 31, 2024, following a £28.9 million fundraise. Operating loss increased to £7.5 million, with R&D expenses at £5.6 million and G&A costs at £2.0 million. The company maintains 39 employees.
e-therapeutics plc (OTC-QX: ETXPF) announced a £13.5 million fundraise through a subscription for ordinary shares at 20p each, managed by M&G Investment Management. This subscription, representing 13.12% of existing capital, will facilitate growth initiatives including expanding their RNAi drug pipeline and developing computational tools. A premium of 12% over the previous closing price was achieved. The issuance is subject to shares being admitted by October 6, 2022. The CEO highlighted the potential of RNAi-based therapies in drug discovery.
FAQ
What is the current stock price of E Therapeutics (ETXPF)?
What is the market cap of E Therapeutics (ETXPF)?
